📄 medicine

Efficacy of the Oral Cholera Vaccine Shanchol® in Preventing Cholera: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

This systematic review and meta-analysis of six randomized controlled trials involving over 627,000 participants demonstrates that two doses of the oral cholera vaccine Shanchol® provide substantial and consistent protection against laboratory-confirmed cholera with an efficacy of approximately 59%, supporting its use alongside water, sanitation, and hygiene interventions to meet global cholera control goals.

Original authors: Lezan Medhat Mohammed, Luay M. Mohammed, Mustafa A. Suraifi, Mohammad A. Jalal, Seyed Saeed Hashemi

Published 2026-06-30

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Lezan Medhat Mohammed, Luay M. Mohammed, Mustafa A. Suraifi, Mohammad A. Jalal, Seyed Saeed Hashemi

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the human body as a bustling city, and the cholera bacteria as a gang of vandals trying to break into the water supply to cause chaos. For decades, health officials have tried to stop these vandals by fixing the pipes and cleaning the streets (what experts call Water, Sanitation, and Hygiene, or WASH). But sometimes, the vandals are too fast, and the city needs a security guard.

This paper is a report card on one specific security guard: a medicine called Shanchol®, which you take by mouth (like a pill or liquid) rather than getting a shot.

Here is the simple breakdown of what the researchers found:

The Big Question

The researchers wanted to know: "If we give people two doses of this oral vaccine, how well does it stop them from getting sick with cholera?"

How They Did the Investigation

Instead of running one new experiment, the authors acted like detectives gathering clues from six different high-stakes investigations (called Randomized Controlled Trials) that had already happened between 2011 and 2019.

The Locations: These investigations took place in India and Bangladesh, places where cholera is a frequent problem.
The Crowd: They looked at data from nearly 628,000 people. That's a huge crowd! About 361,000 people got the vaccine, and about 267,000 people got a "fake" treatment (a placebo) or nothing at all.
The Rules: They only looked at the best kind of evidence: studies where people were randomly assigned to get the vaccine or not, ensuring the results were fair and not biased.

The Results: The "Shield" Works

When the researchers combined all the data, they found that the vaccine worked very well.

The Score: The vaccine reduced the risk of getting cholera by about 59%.
The Analogy: Imagine a group of 100 people walking through a rainstorm of cholera bacteria. Without the vaccine, a certain number would get soaked (sick). With two doses of Shanchol®, about 59 of those people would stay dry.
Consistency: It didn't matter if the area was having a sudden outbreak (an epidemic) or if cholera was always there (endemic). The vaccine acted like a reliable umbrella in both situations.
The Duration: The studies showed this protection lasted for at least three years.

Why This Matters

The paper concludes that this vaccine is a powerful tool. Think of it this way:

WASH (clean water and toilets) is like building a strong wall around the city.
The Vaccine is like giving every citizen a personal shield.

The researchers say you need both. You can't just rely on the wall if it has holes, and you can't rely on shields if the city is flooded with dirty water. But when you use the vaccine alongside clean water initiatives, you get the best protection.

The Caveats (What the paper didn't say)

The authors were careful to note a few limits:

Geography: All the studies happened in South Asia (India and Bangladesh). It's like testing a winter coat in Canada; we know it works there, but we don't know for sure if it works exactly the same way in a tropical jungle in Africa or a desert in Latin America, because the "weather" (bacteria strains and environment) might be different.
The Number of Studies: They only found six major studies to look at. While the results are strong, having more studies from different parts of the world would make the picture even clearer.

The Bottom Line

The paper confirms that taking two doses of the Shanchol® vaccine is a proven, effective way to stop cholera. It's not a magic cure that eliminates the disease entirely, but it cuts the risk of getting sick by more than half. This supports the World Health Organization's plan to use vaccines as a key part of the strategy to drastically reduce cholera deaths by the year 2030.

Technical Summary: Efficacy of the Oral Cholera Vaccine Shanchol® in Preventing Cholera

Problem Statement
Cholera, an acute diarrheal illness caused by Vibrio cholerae, remains a critical global health threat, particularly in low- and middle-income nations with inadequate water, sanitation, and hygiene (WASH) infrastructure. While oral cholera vaccines (OCVs) are recognized as essential components of prevention strategies alongside WASH initiatives, uncertainties persist regarding the magnitude and consistency of their efficacy across different populations and epidemiological settings. Previous studies have reported varying protective effects, influenced by factors such as campaign timing, vaccine coverage, and population mobility. Consequently, there is a need for a comprehensive evaluation of OCV performance, specifically for the killed whole-cell bivalent vaccine Shanchol®, to inform vaccination strategies and policy decisions.

Methodology
This study is a systematic review and meta-analysis of randomized controlled trials (RCTs) conducted in accordance with PRISMA 2020 guidelines and registered with PROSPERO (CRD42022351144).

Search Strategy: A comprehensive search was performed across five electronic databases (PubMed, Scopus, Cochrane Library, EMBASE, and ISI Web of Science) for studies published up to February 2023.
Eligibility Criteria: The review included RCTs comparing two doses of Shanchol® against a placebo or no vaccination in endemic or epidemic regions. Studies were restricted to English language publications with extractable outcome data regarding laboratory-confirmed cholera cases. Observational studies, modeling studies, and trials involving parenteral vaccines were excluded.
Data Synthesis: Six eligible RCTs were identified, involving a total of 627,982 participants (361,119 vaccinated, 266,863 controls). Data were pooled using a random-effects model (DerSimonian–Laird method) to account for between-study variability. Vaccine efficacy (VE) was calculated using the formula $VE = (1 - OR) \times 100$ , where OR is the pooled odds ratio.
Quality Assessment: The risk of bias was assessed using the Cochrane RoB 2 tool, and publication bias was evaluated via funnel plots.

Key Contributions and Results
The analysis synthesized data from six RCTs conducted between 2011 and 2019 in India and Bangladesh.

Pooled Efficacy: The meta-analysis yielded a pooled odds ratio (OR) of 0.41, translating to a vaccine efficacy of 59% (95% CI: 52%–65%; p < 0.001).
Consistency: All six included trials demonstrated statistically significant protection in favor of vaccination. Individual study efficacies ranged from 51% to 67%.
Heterogeneity: Between-study heterogeneity was assessed as moderate ( $I^2 = 40\%$ , p = 0.09), supporting the use of the random-effects model.
Bias Assessment: The methodological quality of the included trials was generally high, with a low risk of bias regarding randomization and outcome measurement. Funnel plot symmetry indicated no significant publication bias.
Duration of Protection: The included studies suggested that protection persists for at least three years, with some trials indicating efficacy over five years.

Significance and Claims
The paper concludes that two doses of Shanchol® provide substantial and consistent protection against laboratory-confirmed cholera, reducing disease incidence by approximately 59%. These findings reinforce the World Health Organization's (WHO) recommendation to utilize OCVs as a complement to WASH interventions for both outbreak response and ongoing endemic control.

The authors assert that the evidence supports the integration of oral cholera vaccination into broader public health strategies. Specifically, the study highlights that expanding vaccine access, combined with sustained improvements in sanitation and surveillance, is essential for achieving the "Global Roadmap to 2030" goal of reducing cholera deaths by 90%. The paper notes that while the findings are robust within the studied contexts (India and Bangladesh), the applicability to other regions with different Vibrio cholerae strains or environmental conditions requires further investigation. The study does not propose new experimental applications but rather validates the current two-dose regimen as an effective tool for cholera control.